Cargando…

Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region

The Global Polio Eradication Initiative has reduced the global incidence of polio by 99% and the number of countries with endemic polio from 125 to 3 countries. The Polio Eradication and Endgame Strategic Plan 2013–2018 (Endgame Plan) was developed to end polio disease. Key elements of the endgame p...

Descripción completa

Detalles Bibliográficos
Autores principales: Fahmy, Kamal, Hampton, Lee M., Langar, Houda, Patel, Manish, Mir, Tahir, Soloman, Chandrasegarar, Hasman, Andreas, Yusuf, Nasir, Teleb, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853409/
https://www.ncbi.nlm.nih.gov/pubmed/28838199
http://dx.doi.org/10.1093/infdis/jix133
_version_ 1783306751570870272
author Fahmy, Kamal
Hampton, Lee M.
Langar, Houda
Patel, Manish
Mir, Tahir
Soloman, Chandrasegarar
Hasman, Andreas
Yusuf, Nasir
Teleb, Nadia
author_facet Fahmy, Kamal
Hampton, Lee M.
Langar, Houda
Patel, Manish
Mir, Tahir
Soloman, Chandrasegarar
Hasman, Andreas
Yusuf, Nasir
Teleb, Nadia
author_sort Fahmy, Kamal
collection PubMed
description The Global Polio Eradication Initiative has reduced the global incidence of polio by 99% and the number of countries with endemic polio from 125 to 3 countries. The Polio Eradication and Endgame Strategic Plan 2013–2018 (Endgame Plan) was developed to end polio disease. Key elements of the endgame plan include strengthening immunization systems using polio assets, introducing inactivated polio vaccine (IPV), and replacing trivalent oral polio vaccine with bivalent oral polio vaccine (“the switch”). Although coverage in the Eastern Mediterranean Region (EMR) with the third dose of a vaccine containing diphtheria, tetanus, and pertussis antigens (DTP3) was ≥90% in 14 countries in 2015, DTP3 coverage in EMR dropped from 86% in 2010 to 80% in 2015 due to civil disorder in multiple countries. To strengthen their immunization systems, Pakistan, Afghanistan, and Somalia developed draft plans to integrate Polio Eradication Initiative assets, staff, structure, and activities with their Expanded Programmes on Immunization, particularly in high-risk districts and regions. Between 2014 and 2016, 11 EMR countries introduced IPV in their routine immunization program, including all of the countries at highest risk for polio transmission (Afghanistan, Pakistan, Somalia, and Yemen). As a result, by the end of 2016 all EMR countries were using IPV except Egypt, where introduction of IPV was delayed by a global shortage. The switch was successfully implemented in EMR due to the motivation, engagement, and cooperation of immunization staff and decision makers across all national levels. Moreover, the switch succeeded because of the ability of even the immunization systems operating under hardship conditions of conflict to absorb the switch activities.
format Online
Article
Text
id pubmed-5853409
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-58534092018-07-01 Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region Fahmy, Kamal Hampton, Lee M. Langar, Houda Patel, Manish Mir, Tahir Soloman, Chandrasegarar Hasman, Andreas Yusuf, Nasir Teleb, Nadia J Infect Dis Supplement Article The Global Polio Eradication Initiative has reduced the global incidence of polio by 99% and the number of countries with endemic polio from 125 to 3 countries. The Polio Eradication and Endgame Strategic Plan 2013–2018 (Endgame Plan) was developed to end polio disease. Key elements of the endgame plan include strengthening immunization systems using polio assets, introducing inactivated polio vaccine (IPV), and replacing trivalent oral polio vaccine with bivalent oral polio vaccine (“the switch”). Although coverage in the Eastern Mediterranean Region (EMR) with the third dose of a vaccine containing diphtheria, tetanus, and pertussis antigens (DTP3) was ≥90% in 14 countries in 2015, DTP3 coverage in EMR dropped from 86% in 2010 to 80% in 2015 due to civil disorder in multiple countries. To strengthen their immunization systems, Pakistan, Afghanistan, and Somalia developed draft plans to integrate Polio Eradication Initiative assets, staff, structure, and activities with their Expanded Programmes on Immunization, particularly in high-risk districts and regions. Between 2014 and 2016, 11 EMR countries introduced IPV in their routine immunization program, including all of the countries at highest risk for polio transmission (Afghanistan, Pakistan, Somalia, and Yemen). As a result, by the end of 2016 all EMR countries were using IPV except Egypt, where introduction of IPV was delayed by a global shortage. The switch was successfully implemented in EMR due to the motivation, engagement, and cooperation of immunization staff and decision makers across all national levels. Moreover, the switch succeeded because of the ability of even the immunization systems operating under hardship conditions of conflict to absorb the switch activities. Oxford University Press 2017-07-01 2017-07-01 /pmc/articles/PMC5853409/ /pubmed/28838199 http://dx.doi.org/10.1093/infdis/jix133 Text en © The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. https://creativecommons.org/licenses/by/3.0/igo This is an Open Access article distributed under the terms of the Creative Commons Attribution 3.0 IGO (CC BY 3.0 IGO) License (https://creativecommons.org/licenses/by/3.0/igo/) which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Supplement Article
Fahmy, Kamal
Hampton, Lee M.
Langar, Houda
Patel, Manish
Mir, Tahir
Soloman, Chandrasegarar
Hasman, Andreas
Yusuf, Nasir
Teleb, Nadia
Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region
title Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region
title_full Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region
title_fullStr Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region
title_full_unstemmed Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region
title_short Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region
title_sort introduction of inactivated polio vaccine, withdrawal of type 2 oral polio vaccine, and routine immunization strengthening in the eastern mediterranean region
topic Supplement Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5853409/
https://www.ncbi.nlm.nih.gov/pubmed/28838199
http://dx.doi.org/10.1093/infdis/jix133
work_keys_str_mv AT fahmykamal introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion
AT hamptonleem introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion
AT langarhouda introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion
AT patelmanish introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion
AT mirtahir introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion
AT solomanchandrasegarar introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion
AT hasmanandreas introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion
AT yusufnasir introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion
AT telebnadia introductionofinactivatedpoliovaccinewithdrawaloftype2oralpoliovaccineandroutineimmunizationstrengtheningintheeasternmediterraneanregion